In the second part of Parallax’s review of 2021, Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, and Dr Ankur Kalra discuss key advances in the field of heart failure and cardiac surgery.
SGLT2 inhibitors are proving to be the blockbuster drug of this decade: Sukh summarises and compares the learnings from DAPA-HF, Emperor-Reduced, and Emperor-Preserved. Next, Sukh highlights the data from SOLOIST-WHF that showed sotagliflozin to have beneficial effects on CV outcomes among patients with type 2 diabetes and HF. Additionally, they discuss how findings on finerenone (FIGARO-DKD) will shape the field. Sukh talks about the semaglutide and the STEP studies, an injectable medication that further expends cardiologist knowledge beyond their speciality. Ankur and Sukh reflect on how the advancement of this field shaped their own practices.
2021 was a busy year for cardiac surgery trials: Sukh and Ankur review the most pertinent data from the AVATAR randomised study presented at AHA 2021. Sukh interprets the outcomes and asks Ankur about his clinical experiences. Finally, they review the investigator led LAAOS III study that showed patients with atrial fibrillation undergoing cardiac surgery, left atrial appendage occlusion was superior to no occlusion.
What were the top practice informing heart failure trials of 2021? What does the latest data say on current cardiac surgery practices? How will these findings inform patient care?
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Brought to you by Edwards: www.edwardstavr.com
Prof Michele Senni is Director of Cardiology at Papa Giovanni XXIII Hospital, Bergamo Italy. He contracted COVID-19 himself and in this latest podcast he meets with Ankur Kalra, MD to discuss his personal experience in dealing with patients and COVID-19 in Europe’s outbreak epicentre.
Hear them discuss the burden on healthcare, patient selection, the importance of testing and PPE and how COVID has resulted in a reduction of acute myocardial infarction and heart failure in patients.
In this latest episode, Ankur Kalra, MD meets with Andrew Sauer, MD, co-author of an upcoming paper in US Cardiology Review on COVID-19 and Cardiovascular Disease that provides a concise and current summary of cardiovascular complications from COVID-19.
Hear them discuss the latest issues surrounding the pandemic, the known cardiac implications and the rapidly emerging data.
Hear Bill’s take on how East Asia responded to and successfully managed the pandemic and how they are now seeing a significant reduction in cases outside the epicentre. Hear how the strategy resulted in only 93 patients in Bill’s city of Nanjing, testing positive for coronavirus with a city population of 8 million.
Learn about effective responses, the importance of early control and how as a cardiovascular physician, your life and practice may be impacted by the virus.
Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
In this episode Ankur Kalra, MD meets with Dr Ann Gage, Cleveland Clinic’s first ‘interventional intensivist’. She discusses her unique skill set, what it means to be an interventionalist in the cath lab but also an expert in cardiovascular intensive care and advocates why such a unique skill set and critical care training are required in today’s modern medicine.
Listen to this engaging discussion between them on the challenges of being a woman in cardiovascular medicine today.
Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Listen to this, as well as an overview on his interesting childhood and his views on the future of cardiac imaging to treat TAVR.
Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.